Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $9.89 down -2.47% from its previous closing price of $10.14. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 5.92 million shares were traded. MLTX stock price reached its highest trading level at $10.25 during the session, while it also had its lowest trading level at $9.48.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.65 and its Current Ratio is at 16.65. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 01, 2025, Goldman Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Wolfe Research Downgraded its Outperform to Underperform on September 30, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 08 ’25 when Bodenstedt Matthias bought 10,870 shares for $9.09 per share. The transaction valued at 98,808 led to the insider holds 627,536 shares of the business.
Chen Bihua sold 6,494,151 shares of MLTX for $46,827,628 on Sep 29 ’25. The Former 10% Owner now owns 2,000,000 shares after completing the transaction at $7.21 per share. On Sep 30 ’25, another insider, Chen Bihua, who serves as the Former 10% Owner of the company, sold 5,827 shares for $6.96 each. As a result, the insider received 40,556 and left with 1,994,173 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 628028864 and an Enterprise Value of 282925856.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.03, which has changed by -0.7891015 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is -77.02%, while the 200-Day Moving Average is calculated to be -77.29%.
Shares Statistics:
For the past three months, MLTX has traded an average of 3.86M shares per day and 10243100 over the past ten days. A total of 63.47M shares are outstanding, with a floating share count of 55.13M. Insiders hold about 13.18% of the company’s shares, while institutions hold 81.30% stake in the company. Shares short for MLTX as of 1759190400 were 5771368 with a Short Ratio of 1.50, compared to 1756425600 on 5176424. Therefore, it implies a Short% of Shares Outstanding of 5771368 and a Short% of Float of 20.39.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.8 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$3.17 and -$3.52 for the fiscal current year, implying an average EPS of -$3.33. EPS for the following year is -$3.58, with 9.0 analysts recommending between -$1.83 and -$4.36.
